Advice
following a full submission
dexamethasone intravitreal implant (Ozurdex®) is accepted for use within NHS Scotland.
Indication under review: treatment of adult patients with visual impairment due to diabetic macular oedema who are pseudophakic or who are considered insufficiently responsive to, or unsuitable for non-corticosteroid therapy.
Intravitreal dexamethasone improved visual acuity more than sham treatment in adult patients who were pseudophakic or had received prior treatment for diabetic macular oedema, based on subgroup analyses.
Download detailed advice209KB (PDF)
Medicine details
- Medicine name:
- dexamethasone (Ozurdex)
- SMC ID:
- 1046/15
- Indication:
- Treatment of adult patients with visual impairment due to diabetic macular oedema who are pseudophakic or who are considered insufficiently responsive to, or unsuitable for non-corticosteroid therapy.
- Pharmaceutical company
- Allergan Ltd
- BNF chapter
- Eye
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 11 May 2015